Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Belén Peiró-AventínDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Majadahonda, Spain (B.P.-A., M.B., E.G.-L., F.D., P.G.-P.).ORCID 0000-0001-9081-7003
Elena Revuelta-LopezCardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain (E.R.-L., E.G.-L., A.C., M.R.-C., J.L., A.B.-G.).ORCID 0000-0001-8962-5936
Mariana BrandaoDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Majadahonda, Spain (B.P.-A., M.B., E.G.-L., F.D., P.G.-P.).ORCID 0000-0001-9913-0435
Julio NuñezCIBERCV, Instituto de Salud Carlos III, Madrid, Spain (E.R.-L., J.N., E.G.-L., F.D., M.R.-C., J.L., A.B.-G., P.G.-P.).ORCID 0000-0003-1672-7119
Manuel A Fernández-RojoCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (B.P.-A., M.A.F.-R., R.M.C., E.G.-L., P.G.-P.).ORCID 0000-0002-2240-1951
Rosa M CarmonaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (B.P.-A., M.A.F.-R., R.M.C., E.G.-L., P.G.-P.).
Borja MontejoICREC Research Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain (E.R.-L., B.M., A.B.-G.).ORCID 0009-0000-4837-5109
Alejandro Ferrando-MuñozDepartment of Biochemistry, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain (A.F.-M., A.J.-M.).
Aránzazu Martín-García
Esther Gonzalez-LopezDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Majadahonda, Spain (B.P.-A., M.B., E.G.-L., F.D., P.G.-P.).ORCID 0000-0003-4175-1487
Fernando DominguezDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Majadahonda, Spain (B.P.-A., M.B., E.G.-L., F.D., P.G.-P.).ORCID 0000-0001-8408-363X
Andrea CamblorCardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain (E.R.-L., E.G.-L., A.C., M.R.-C., J.L., A.B.-G.).ORCID 0009-0005-0592-598X
María Ruiz-CuetoCardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain (E.R.-L., E.G.-L., A.C., M.R.-C., J.L., A.B.-G.).ORCID 0009-0002-7835-3722
Josep LuponCardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain (E.R.-L., E.G.-L., A.C., M.R.-C., J.L., A.B.-G.).
Sergio TeryuaClinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian/Columbia University Irving Medical Center, New York, NY (S.T., D.B., M.S.M.).ORCID 0000-0002-4653-9330
Dimitrios BampatsiasClinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian/Columbia University Irving Medical Center, New York, NY (S.T., D.B., M.S.M.).
Israt JahanCardiovascular Institute, Oregon Health and Science University, Portland, OR (I.J., A.M.).ORCID 0000-0003-0948-8439
Ana RoyuelaClinical Biostatistics, Puerta de Hierro Biomedical Research Institute (IDIPHISA), CIBERESP, Madrid, Spain (A.R.).ORCID 0000-0003-1665-081X
Ahmad MasriDepartment of Biochemistry, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain (A.F.-M., A.J.-M.).ORCID 0000-0002-6390-6526
Mathew S MaurerClinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian/Columbia University Irving Medical Center, New York, NY (S.T., D.B., M.S.M.).ORCID 0000-0001-5400-5008
Antoni Bayes-GenisCardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain (E.R.-L., E.G.-L., A.C., M.R.-C., J.L., A.B.-G.).ORCID 0000-0002-3044-197X
Pablo Garcia-PaviaDepartment of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Majadahonda, Spain (B.P.-A., M.B., E.G.-L., F.D., P.G.-P.).ORCID 0000-0002-5470-2257
Funding
SCAN-MP (Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations) COVID-19 SuppplementR01HL139671 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S, RUBERG, FREDERICK LIEF · 2019 to 2023
$7.4M
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac AmyloidosisR01AG081582 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MATHEW S MAURER · 2023 to 2026
backgroundWith the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the prognostic value of multiple circulating biomarkers for predicting outcomes in ATTR-CM.
methodsWe evaluated 12 different circulating biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin I [hsTnI], mid-regional pro-adrenomedullin [MR-proADM], carbohydrate antigen 125 [CA125], soluble suppressor of tumorigenicity 2 [sST2], cluster of differentiation antigen 146 [CD146], growth/differentiation factor-15 [GDF-15], alpha-klotho, fibroblast growth factor 23 [FGF-23], galectin-3, insulin-like growth factor-binding protein 7 [IGFBP-7], and estimated glomerular filtration rate [eGFR]) in 337 ATTR-CM patients from Spain. Cox models were employed to determine their predictive abilities. Findings were validated in 2 independent external cohorts of 210 patients from the United States and 416 patients from the ATTR-ACT trial, respectively.
resultsOver a median follow-up of 19.7 months (IQR, 6.5-42.3), 67 patients (19.9%) died/underwent heart transplantation, and 81 (24%) had heart failure events. MR-proADM was the biomarker with the strongest prognostic performance, with a C-index of 0.788 (95% CI, 0.723-0.851) for all-cause mortality and 0.721 (95% CI, 0.669-0.772) for the composite endpoint of death and heart failure events. MR-proADM was associated with multiple parameters of ATTR-CM severity and was independently associated with mortality, heart failure events, and the composite endpoint. MR-proADM ≥1.1 nmol/L was identified as the optimal prognostic threshold, and it improved prediction of mortality when added to the National Amyloid Center (area under the curve [AUC], 0.682 versus 0.737;
conclusionsIn patients with ATTR-CM, MR-proADM levels are associated with disease severity and worse prognosis. MR-proADM improves prediction of all-cause mortality and captures heart failure events.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis. · full record | Socratic